Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyShaji Kumar, J Feather, Antje Hoering et al.|Leukemia|2011Cited by 721
Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple MyelomaAshraf Badros, Steven Grant|Clinical Cancer Research|2009Cited by 230
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working GroupMeletios Α. Dimopoulos, Evangelos Terpos, Giampaolo Merlini et al.|The Lancet Oncology|2023Cited by 120
Safety and efficacy of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma: Results from the phase 1b MagnetisMM-30 trialAttaya Suvannasankha, Alexander M. Lesokhin, Ashraf Badros et al.|Blood|2025Cited by 6